pPACK-SPIKE™ Omicron (B.1.1.529) Variant Lentivector Packaging Mix

Overview

Safely study SARS-CoV-2 interactions 

Highly transmissible, the SARS-CoV-2 Omicron variant (B.1.1.529) was classified as a variant of concern by the Centers for Disease Control (CDC) in the United States on November 30, 2021. With the pPACK-SPIKE™ Omicron (B.1.1.529) Variant Spike Protein Lentivector Packaging Mix, you can safely characterize the SARS-CoV-2 S1 spike protein from lineage Omicron (B.1.1.529), which contains the following mutations:

A67V, Δ69-70, T95I, Δ142-144, Y145D, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S,Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F

Designed to efficiently package most third-generation lentivectors, the pPACK-SPIKE Omicron Variant Lentivector Packaging Mix speeds and simplifies the preparation of lentiviral particles pseudotyped with the SARS-CoV-2 Spike glycoprotein containing the mutations in the Omicron variant.

Based on SBI's highly cited pPACKH1 packaging system but with a truncated SARS-CoV-2 Omicron variant Spike protein [1] replacing the standard VSV-G envelope protein, the pPACK-SPIKE Packaging Mix consists of three plasmids that produce all of the structural and  replication proteins needed to transcribe and package an RNA copy of an expression lentivector into recombinant, “Spike” pseudotyped lentiviral particles. As a result, you can conduct a range of SARS-CoV-2 studies under BSL-2 conditions, including neutralization assays, studies of virus interactions with host surface proteins, and the development of vaccines and therapeutics.

For added convenience we also offer pPACK-BALD™, an envelope protein-free lentivector packaging mix that can be used as a negative control for pPACK-SPIKE studies, or for creating lentivirus particles pseudotyped with the envelope protein of your choice. 

• Based on SBI’s popular and highly cited pPACKH1 Packaging System
• Uses codon-optimized SARS-CoV-2 “S” protein from variant Omicron (B.1.1.529) in place of VSV-G envelope protein
• Spike protein mutations are A67V, Δ69-70, T95I, Δ142-144, Y145D, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S,Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F
• Ideal for COVID-19 research, such as neutralization assays, under BSL2 conditions
• Package any 3rd-generation lentivector reporter of your choice, including SBI’s popular LentiLabeler reporters
• Available as a packaging mix or bundled into a convenient kit that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution
• Use with pPACK-BALD™, an envelope protein-free lentivector packaging system that is an ideal negative control

The pPACK-SPIKE Omicron Variant Lentivector Packaging Mix is available as stand-alone packaging mixes with sufficient plasmids for 10 reactions (standard size) or 25 reactions (XL), as well as in a convenient kit format that includes PureFection™ Transfection Reagent and PEG-it Virus Precipitation Solution.

See all of the available pPACK-SPIKE S protein variants:

References

1. Ou X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. commun. 2020 Mar 27; 11(1):1620.doi: 10.1038/s41467-020-15562-9. PMCID: PMC7100515.